首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1625002

全球癌症診斷市場規模（按診斷類型、癌症類型、地區、範圍和預測）

Global Cancer Diagnostics Market Size By Diagnostic Type (Biopsy And Cytology Tests, Diagnostic Imaging Tests), By Cancer Type (Breast Cancer, Leukemia), By Geographic Scope And Forecast

出版日期: 2024年10月29日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

癌症診斷市場規模及預測

2024 年癌症診斷市場規模價值 1117 億美元，預計到 2031 年將達到 1884.3 億美元，在 2024-2031 年預測期內的複合年增長率為 6.77%。由於生物標記、影像等各個領域的技術進步不斷進步，癌症患者數量不斷增加，老年人口迅速增加，政府宣傳活動不斷開展，政府資金不斷增加，全球癌症診斷市場預計將出現強勁增長。了這一目標。本報告對全球癌症診斷市場進行了全面的評估。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

定義全球癌症診斷市場

癌症是全球最常見的疾病之一。檢測癌症的過程涉及使用專門用於診斷的某些技術和設備。透過正確且提前的診斷可以預防和控制癌症死亡。當患者出現癌症跡象時，癌症診斷即確認其患有癌症。早期診斷可以實現有效治療並確保患者的生存機會。進行有效的診斷測試以確認或排除疾病的存在，監測疾病的進程，規劃治療並確定治療的有效性。

在某些情況下，重新檢測可能很重要，例如當患者的病情有所改善、所採集樣本的品質較差或需要確認異常的檢測結果時。癌症的診斷方法包括影像學檢查、實驗室檢查（包括腫瘤標記）、腫瘤活檢、內視鏡檢查、手術和基因檢測。癌症診斷從體檢開始。這使得可以檢測癌症疾病常見的特定生物標記和蛋白質並進行診斷。檢測癌症的另一個重要過程涉及使用專門用於診斷的某些技術和設備。

全球癌症診斷市場概覽

全球癌症診斷市場的主要驅動力是創新產品的不斷推出以及對各種疾病早期診斷的需求日益增長。此外，醫療保健和診斷領域的快速成長歸功於技術先進的檢測系統，這些系統更新了腫瘤篩檢方法，能夠提供可靠的結果。癌症發生率的不斷上升刺激了用於監測疾病進展的篩檢測試和診斷影像市場的發展，從而推動了市場的成長。

根據世界衛生組織 (WHO) 的數據，癌症是全球第二大死因，2018 年促使約 960 萬人死亡。美國國家癌症研究所（NCI）確定，到2030年，每年新發生癌症病例數將達2,360萬人。此外，癌症診斷領域的研究和開發也有望促進市場成長。例如，2020 年 1 月，葡萄牙波爾圖大學的研究人員使用糖工程胃癌模型證明了針對 CD44v9（人類胃腸道癌細胞中表達的主要蛋白質剪接變體）的單克隆抗體的效力。糖基化在檢測中的作用。

然而，不良的報銷政策預計會阻礙市場成長。近年來，放射學領域在診斷影像設備方面取得了許多進展。大多數健康保險公司不會為使用電腦輔助檢測 (CAD) 的程式提供報銷。此外，癌症檢測軟體的高成本也有望阻礙市場成長。電腦輔助檢測 (CAD) 軟體的許可證有效期為一年，醫院必須每年更新。儘管如此，寄生蟲癌症活檢平台的開發預計將為全球癌症診斷市場參與者提供豐厚的成長機會。此外，人工智慧在快速癌症檢測中的應用也有望促進市場成長。

Cancer Diagnostics Market size was valued at USD 111.70 Billion in 2024 and is projected to reach USD 188.43 Billion by 2031 , growing at a CAGR of 6.77% during the forecast period 2024-2031. The global Cancer Diagnostics Market has witnessed strong growth owing to the increasing technological advancements in various fields such as biomarkers, imaging, etc., a growing number of cancer cases, rapid growth in the geriatric population, awareness actions by governments, and growing government funding. The Global Cancer Diagnostics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Cancer Diagnostics Market Definition

Cancer is one of the most popular comprehensive diseases in the world. The process of detecting cancer includes the usage of certain technology and devices specifically used in its diagnosis. Cancer deaths can be prevented and controlled due to proper and prior diagnosis. A cancer diagnosis is defined as the identification of cancer in patients who have developed the signs of the disease. Early diagnosis leads to effective treatment and secures the survival chances of the patient. Effective diagnostic testing is practiced to confirm or exclude the presence of disease, monitor the disease process, and plan for and decide the effectiveness of treatment.

In some cases, it is important to repeat testing when a person's condition has improved, if a sample received was not of good quality, or if an abnormal test result needs to be confirmed. Diagnostic ways for cancer may involve imaging, laboratory tests (including inspections for tumor markers), tumor biopsy, endoscopic examination, surgery, or genetic testing. Cancer diagnosis begins with a physical checkup. The detection of certain biomarkers and proteins that are common in cancer disorders thereby, results in the diagnosis process. Remarkable another process of detecting cancer includes the usage of certain technology and devices particularly used in its diagnosis.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cancer Diagnostics Market Overview

The global Cancer Diagnostics Market is principally driven by the continual introduction of innovative products, coupled with a growing need for early diagnosis of various diseases. Also, the rapid growth of the healthcare and diagnostics sector can be assigned to the entrance of technologically advanced laboratory systems that have updated oncological screening in producing reliable results. The increasing incidence of cancer is triggering the market for these screening tests and imaging modalities used for observing disease progression, thereby driving the market growth.

According to the World Health Organization (WHO), cancer was the second-leading reason for death globally, subject to approximately 9.6 million deaths in 2018. The National Cancer Insititute (NCI) has determined the number of new cancer cases per year reaches 23.6 million by 2030. Moreover, R&D in cancer diagnostics is also anticipated to aid in the growth of the market. For instance, in January 2020, researchers from Universidade do Porto, Portugal, reported an assessment of the role of O-glycosylation using glycoengineered gastric cancer models in the detection of CD44v9 - a major protein splice variant is forms expressed in human gastrointestinal cancer cells-by monoclonal antibodies.

However, inadequate reimbursement policies are expected to hinder the growth of the market. There have been various advancements in radiology about imaging equipment in the recent past. Most medical insurance companies do not provide reimbursement for procedures utilizing Computer-aided Detection (CAD). Moreover, the high price of cancer detection software is also anticipated to hinder the growth of the market. Computer-aided detection (CAD) software is available with a one-year license and hospitals to have to renew it every year. Nonetheless, the development of biopsy platforms for associate animal cancers is expected to offer profitable growth opportunities for players in the global Cancer Diagnostics Market. Moreover, the use of AI in quick detection of cancer is also supposed to aid in the growth of the market.

Global Cancer Diagnostics Market Segmentation Analysis

The Global Cancer Diagnostics Market is segmented based on Diagnostic Type, Cancer Type, and Geography.

Cancer Diagnostics Market, By Diagnostic Type

Biopsy and Cytology Tests
Diagnostic Imaging Tests
Endoscopy
Genetic Tests
Others
Based on Diagnostic Type, the market is bifurcated into Biopsy and Cytology Tests, Diagnostic Imaging Tests, Endoscopy, Genetic Tests, and Others. The Diagnostic Imaging Tests segment has dominated the major market share and is estimated to witness the highest CAGR for the forecast period. Imaging modalities such as Computed Tomography (CT) scan and Magnetic Resonance Imaging (MRI) are fast, non-invasive, and pain-free diagnostic explications. These imaging modalities are applied as supportive tests along with other laboratory and genetic tests to discover the location and sharpness of the condition in diagnosing a different type of cancer, thereby helping in the choice of a suitable treatment regimen

Cancer Diagnostics Market, By Cancer Type

Breast Cancer
Leukemia
Pancreatic Cancer
Prostate Cancer
Colon and Rectal Cancer
Others

Based on Cancer Type, the market is bifurcated into Breast Cancer, Leukemia, Pancreatic Cancer, Prostate Cancer, Colon and Rectal Cancer, and Others. The Breast Cancer segment is estimated to witness the highest CAGR for the forecast period. The significant causes leading to an upsurge in breast cancer prevalence and percentage rates are hormone replacement therapy, obesity, reduced childbearing and age-related dangers. Transforming lifestyles and increased drink consumption can be directly linked with breast cancer prevalence as well as measure, as it results in an increase in estrogen levels in the body.

Cancer Diagnostics Market, By Geography

North America
Europe
Asia Pacific
Rest of the world.

Based on Regional Analysis, the Global Cancer Diagnostics Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America dominated the market by capturing the largest revenue share and is expected to continue its lead throughout the forecast period owing to factors such as more prominent funding available for research and development plans and the huge adoption of advanced technologies. The presence of various biotechnology as well as medical device companies in this region is also one of the principal factors driving the diagnostics sector in the region. The Asia Pacific is also expected to grow at a significant rate due to the availability of skilled technicians at a comparatively lower price and a defined regulatory framework favoring advanced product approvals.

Key Players

The "Global Cancer Diagnostics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Illumina, Inc., Koninklijke Philips N.V., Agilent Technologies, Inc., General Electric Company, F. Hoffmann-La Roche Ltd, and Becton, Dickinson, and Company.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

Product Launches and Merchandise Expansions
In Nov 2021, Becton, Dickinson, and Co., a key medical devices company, launched a machine-controlled high-throughput diagnostic system for cervical cancer screening, dubbed the Bachelor of Divinity COR PX/GX System.
In August 2021, the system Approved by the U.S. Food and Drug Administration has been designed to be used in centralized labs and might handle the high-volume process with exaggerated potency.
Partnerships, Collaborations, and Agreements
In 2020, GE aid entered a partnership with GenesisCare to boost patient outcomes for the 2 biggest health burdens globally, cancer and cardiovascular disease. GE aid can give CT, MRI, PET/CT, SPECT, digital diagnostic techniques, and ultrasound instrumentation to GenesisCare's 440+ cancer and upset treatment centers across Australia, the US, the UK, and Spain.
In 2020, Roche medicine entered a partnership with Illumina to supply broad access to clinical medical specialty next-generation sequencing.
Mergers and Acquisition
In March 2021, Agilent Technologies INC. nonheritable Resolution natural science, to bolster its headship position in cancer medicine.
In September 2020, Illumina, Inc.'s nonheritable goblet launched a brand-new section of cancer diagnosing. This acquisition is aimed to accelerate the adoption and commercialization of transformative multi-cancer diagnosing tests with the possibility to observe a lot of cancers earlier and alter higher outcomes.

1 INTRODUCTION OF GLOBAL CANCER DIAGNOSTICS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CANCER DIAGNOSTICS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE

5.1 Overview
5.2 Biopsy and Cytology Tests
5.3 Diagnostic Imaging Tests
5.4 Endoscopy
5.5 Genetic Tests
5.6 Others

6 GLOBAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

6.1 Overview
6.2 Breast Cancer
6.3 Leukemia
6.4 Pancreatic Cancer
6.5 Prostate Cancer
6.6 Colon and Rectal Cancer
6.7 Others

7 GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East & Africa

8 GLOBAL CANCER DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Illumina, Inc.
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Koninklijke Philips N.V.
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Agilent Technologies, Inc.
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 General Electric Company
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 F. Hoffmann-La Roche Ltd.
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Becton, Dickinson and Company
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments